Results 151 to 160 of about 19,752 (209)

Baseline intact fibroblast growth factor 23 and risk of kidney disease progression in the Indian Chronic Kidney Disease cohort: a prospective multicenter study. [PDF]

Front Med (Lausanne)
Kamboj K, Yadav AK, Rastogi A, Ghosh A, Sharma S, Jain L, Kumar V, Jha V, Indian Chronic Kidney Disease Study Network.   +8 more
europepmc   +1 more source

High Phosphate Load Induces De Novo Formation of Tertiary Lymphoid Structures in the Kidney. [PDF]

FASEB J
Weingärtner N, Richter B, Walles F, Kapanadze T, Schmitz J, Bräsen JH, Limbourg FP, Haffner D, Leifheit-Nestler M.   +8 more
europepmc   +1 more source

Iron-Induced Hypophosphatemia: A Review of Pathophysiology, Drug Safety, and Pharmacogenomic Perspectives. [PDF]

J Hematol
Pozzessere S.
europepmc   +1 more source

Serum Calcium as a Determinant of Fibroblast Growth Factor 23 Levels in Patients With Primary Hyperparathyroidism and Graves' Disease. [PDF]

Cureus
Yamashita H, Mori Y, Imanishi Y, Shindo H, Tatsushima D, Tachibana S, Fukuda T, Takahashi H, Nagayama Y, Satoh S.   +9 more
europepmc   +1 more source

FGF23 wt Allele [PDF]

, 2020
openaire   +1 more source

Circulating fibroblast growth factor 23 and physical performance in middle-aged and older adults with normal kidney function. [PDF]

Sci Rep
Kosaki K, Mori S, Matsui M, Saito C, Kuro-O M, Yamagata K, Maeda S.   +6 more
europepmc   +1 more source

Metabolic Bone Disease in Captive Flying Foxes: A Conceptual Framework and Future Perspectives. [PDF]

Metabolites
Faim D, Pires I, Silva F.
europepmc   +1 more source

Bone Phenotype in Autosomal Dominant Polycystic Kidney Disease. [PDF]

Calcif Tissue Int
Jankowska M, Magnusson P, Debowska M, Lindholm B, Qureshi AR, Lukaszuk T, Dębska-Ślizień A, Fuster DG, Stenvinkel P, Haarhaus M.   +9 more
europepmc   +1 more source

Editorial: Phosphate handling: from cells to human. [PDF]

Front Endocrinol (Lausanne)
Abate V, Menale C, De Filippo G.
europepmc   +1 more source

Case Report: Increased FGF23 and new insufficiency fractures at burosumab discontinuation in X-linked hypophosphatemia. [PDF]

Front Endocrinol (Lausanne)
Bandir R, Zanisi L, Nicod-Lalonde M, Gonzalez-Rodriguez E.   +3 more
europepmc   +1 more source